Page 156 - 2019_01-Haematologica-web

R. Gressin et al.
RH, et al. Phase II multicenter study of ben-
damustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(27):4473-4479.
16. Klapper W, Hoster E, Determann O, et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop. 2009;2(2):103-111.
17. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009;50(8):1257-1260.
18. Gimenez E, Chauvet M, Rabin L, et al. Cloned IGH VDJ targets as tools for per- sonalized minimal residual disease moni- toring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucemies et Autres Maladies du Sang. Br J Haematol. 2012;158(2):186-197.
19. Pott C, Schrader C, Gesk S, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation pre- dicts long-term remission in mantle cell lymphoma. Blood. 2006;107(6):2271-2278.
20. Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent pre- dictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115(16): 3215-3223.
21. Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow- up after intensive immunochemotherapy for untreated mantle cell lymphoma fol- lowed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158(3):355-362.
22. Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged
65 years or younger with mantle cell lym- phoma (MCL younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565-575.
23. Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell trans- plantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250-1260.
24. Visco C, Chiappella A, Nassi L, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2017;4(1):e15-e23.
25. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous adminis- tration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431-440.
26. Magrangeas F, Kuiper R, Avet-Loiseau H, et al. A genome-wide association study iden- tifies a novel locus for bortezomib-induced peripheral neuropathy in european patients with multiple myeloma. Clin Cancer Res. 2016;22(17):4350-4355.
27. Bodet-Milin C, Touzeau C, Leux C, et al. Prognostic impact of 18F-fluoro-deoxyglu- cose positron emission tomography in untreated mantle cell lymphoma: a retro- spective study from the GOELAMS group. Eur J Nucl Med Mol Imaging. 2010;37(9): 1633-1642.
28. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lym- phoma. Blood. 2008;111(2):558-565.
29. Cheminant M, Derrieux C, Touzart A, et al. Minimal residual disease monitoring by 8- color flow cytometry in mantle cell lym- phoma: an EU-MCL and LYSA study. Haematologica. 2016;101(3):336-345.
30. Drandi D, Ferrero S, Ladetto M. Droplet digital PCR for minimal residual disease detection in mature lymphoproliferative
disorders. Methods Mol Biol. 2018;1768:
229-256.
31. Scherer F, Kurtz DM, Newman AM, et al.
Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8(364):364ra155.
32. Scherer F, Kurtz DM, Diehn M, Alizadeh AA. High-throughput sequencing for non- invasive disease detection in hematologic malignancies. Blood. 2017;130(4):440-452.
33. Camus V, Jardin F, Tilly H. The value of liq- uid biopsy in diagnosis and monitoring of diffuse large B-cell lymphoma: recent developments and future potential. Expert Rev Mol Diagn. 2017;17(6):557-566.
34. Delfau-Larue MH, van der Gucht A, Dupuis J, et al. Total metabolic tumor vol- ume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lym- phoma. Blood Adv. 2018;2(7):807-816.
35. Luskin MR, Murakami MA, Manalis SR, Weinstock DM. Targeting minimal residual disease: a path to cure? Nat Rev Cancer. 2018;18(4):255-263.
36. Kolstad A, Pedersen LB, Eskelund CW, et al. Molecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; results from the mordic mantle cell lym- phoma studies (MCL2 and MCL3) with median follow-up of 8.5 years. Biol Blood Marrow Transplant. 2017;23(3):428-435.
37. Andersen NS, Pedersen LB, Laurell A, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol. 2009;27(26):4365-4370.
38. Rummel MJ, Knauf W, Goener M, et al. Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multi- center phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). J Clin Oncol. 2016;34(15_suppl):7503.
146
haematologica | 2019; 104(1)